Awakn Life Sciences has announced that they have closed a non-brokered private placement through the issuance of 2,031,250 units at a price of $1.60 per Unit for gross proceeds of $3,250,000.
Category Press Release
Published in Bloomberg
Companies Featured
Awakn Life SciencesAWAKN Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.